. . , , ..

75-80% , ,
,
. 1,2,3
, per se,
.
( , , C,
, stress), , ,

.

.

aldose reductase (. 1).

.
sorbitol, fructose.
sorbitol aldose reductase DPH,
, .

stress. 4,5

AGEs:

.

 . H
( Schiff),
( Amadori, Amadori ,
).
(
)
(AGEs).
AGEs
AGEs ( RAGE) ,
RAGEs (. 2).
( ,
IV, , .)
. ,
LDL.
AGEs, (RAGEs)
NF-kB 2 stress.
E, AGEs RAGEs
, .
AGEs RAGEs
interleukin -1, o TNF-a, o PDGF, o IGF -1,
.
AGEs RAGEs
, AGEs
. 4,6,7,8,9,10

C
PKC 11 . PKC .
PKC
PKC, (DAG). DAG
.

 PKC
AGEs ,
.
PKC .
m-RNA ().
1 .
NEGF .
transforming growth factor- (TGF-),
.
- 1 NF-kB (
) NAD(P)H
(2). 4,5,6,7

HESOSAMINE
H
(: , Crembs,
glucose-6-phosphate fructose -6-phosphate.
,
GFAT ( glutamine fructose-6- phosphate ammotransferase) glucosanine -6- phosphate
UDP (urinine disphosphate) glucosamine ( hesosamine). glucosamine serine
threonine (
-1, TGF- 1,.) (. 3).4,6

STRESS
To stress 2

.
stress (
), .
stress .

 ()

, .
Amadori.
(-2)

( 22).
,

.
, ,
C 40-50%
.
stress

.

( , , , V).
. NADH FADH2
. Q C
, , V 2 2.

, Synthase .
, (VCPs)
.
, ,
, ,
.
V
Q 2 ( ) (. 4).

(ROS). ROS DNA
poly- ADP ribose- polymerase (PARP).
PARP NAD+ (
)
GAPDH.

 GAPDH .
, GAPDH

(, AGEs, , PKC) (. 5).
stress
( ),
GAPDH.
O Brownlee ( )
GAPDH ADP ribose
(AGEs, Prot. Kinase C, exosamine, polyol).
T stress
.
stress

(FFA).
FFA, 90 -92% .
FFA
( ) FFA .
FFA (NADH FADH2)
2. (ROS).
FFA stress
. 6,11,12,13,14

,
.
, .
. VII,
,

Von Willebrand ,

,
( C).

() .

 .
I, , ,
Von Willebrand .
,
C (PKC) .
(Ca),

(,ADP, 2, .) 6,16,17,18,19

.
,
.
,
( )
.
. (AGEs) ,
(PAF, IGF-1, MCF, TGF-)
. AGEs
, .

, .
,
,
.

, ,
.

.
. 6,8,9,20,21


( vasavasorum) ,
. ,
/
.
.

1 2.
1 , 2
. 5,7,15,16

(nitric oxide- NO), ,
, , .
- ( )
.
(.. methacholine) 2- ( 1
2), .
, (NOS) , ().
(, (),
) .
stress
dimethylarginine (ADMA) NOS.

() . -3 ( NOS)
, PKC
.
VLDL.
,
HDL VLDL ( ), LDL
LDL.

 LDL ,
, ,
.
, LDL
, . LDL
.
.

NOS -3 Alt .
.
.

.
-3
NOS . ,

-1 (

) .

.
,
, .

.

, .
, , ,
,
.
stress
( AGEs,
. C .).

, ,
.
.

 1.

(AGEs)

2.

3.

ROS

4.

10


1)

. , . 156. Med Gr cent. 1999

2)

. .
, . 2004: 283 -302.

3)

Schneider DJ, Moore JW. Diabetes and thrombosis. In: Johnstone MT, Veves A, eds. Diabetes and
cardiovascular disease. Towova, NJ:

Humana Pr; 2001; 149 -168. J Invasive Cardiol. 2001

Apr;13(4):306-9.
4)

Beckman J, Greagen M, Libby P. Diabetes and Atherosclerosis. JAMA 2002; 287: 2570 -2581.

5)

Eckel RH, Wassef M, Chait A, et al. Pathogenesis of Atherosclerosis in diabetes. Circulation 2002;
105: e138 -43.

6)

M. Browlee. he pathobiology of Diabetic Complications. Diabetes 2005; 54: 1615 -1624.

7)

Moreno P, Fuster V: New aspects in the pathogenesis of diabetic atherothrombosis. JACC 2004; 44:
2293 -300.

8)

Sato T, Iwaki M, Shimogaito N, et al. TAGE (toxic AGEs) theory in diabetic complications. Curr

Mol Med. 2006 May;6(3):351-8. Review.

11

9)

Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated
atherosclerosis

in

diabetes:

pathogenic

and

therapeutic

implications.

J Lab Clin Med. 2006 May;147(5):211-9. Review.

10)

Omsland TK, Bangstad HJ, Berg TJ, et al. Tidsskr Nor Laegeforen. 2006 Jan 12;126(2):155-8.
Review.

11)

Mehta JL, Rasouli N, Sinha AK, et al. Oxidative stress in diabetes: a mechanistic overview of
its

effects

on

atherogenesis

and

myocardial

dysfunction.

Int J Biochem Cell Biol. 2006;38(5-6):794-803. Epub 2006 Jan 18. Review.
12)

jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications.
Free Radic Biol Med. 2006 Jan 15;40(2):183-92. Epub 2005 Nov 10. Review.

13)

Schranwen P, Hesselink M: Oxidative capacity lipotoxicity and mitochondrial damage in type 2

diabetes. Diabetes 2004; 53: 1412 -1417.

14)

Ceriello A. New insights on oxidative stress and diabetic complications may lead to a causal
antioxidant therapy. Diabetes Care 2003; 26: 1589-96.

15)

Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24:
1476 -85.

16)

Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years.
Thromb Haemost. 2006 Jan;95(1):49-55. Review.

17)

Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus.

Circ Res 2001; 88: E14 -22.

18)

Wheatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance
on vascular endothelial dysfunction. Diab. medic. 2003; 20: 255 -268.

19)

Renard C, Van Obberghen E. Role of diabetes in atherosclerotic pathogenesis. What have we

learned from animal models?
Diabetes Metab. 2006 Feb;32(1):15-29. Review.

20)

Yamagishi S, Nakamura K, Matsui T, et al. Cardiovascular disease in diabetes.

Mini Rev Med Chem. 2006 Mar;6(3):313-8. Review.

21)

Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes.

Diabetes Metab Res Rev. 2006 Jan-Feb;22(1):4-10. Review.

12